CLINICAL APPLICATION OF AUTOLOGOUS WHOLE BONE MARROW STEM CELL TRANSPLANTATION FOR CRITICAL LIMB ISCHEMIA WITH BUERGERS DISEASE

doi:10.4066/biomedicalresearch-C2-006

CLINICAL APPLICATION OF AUTOLOGOUS WHOLE BONE MARROW STEM CELL TRANSPLANTATION FOR CRITICAL LIMB ISCHEMIA WITH BUERGERS DISEASE

Joint Event on International Conference on CARDIOLOGY AND CARDIOVASCULAR MEDICINE & International Conference on STEM CELLS AND REGENERATIVE MEDICINE
June 18-19, 2018 | Osaka, Japan

Dong-ik Kim

Samsung Medical Centre, South Korea

Posters & Accepted Abstracts : Biomed Res

DOI: 10.4066/biomedicalresearch-C2-006

Abstract:

KoreaOur goal was to evaluate early results of the clinical application of autologous whole bone marrow stem cell transplantation (AWBMSCT) for critical limb ischemia (CLI) in patients with Buerger’s disease. We retrospectively analyzed the data of 58 limbs of 37 patients (mean age, 43.0 years; range, 28-63 years; male, 91.9%) with Buerger’s disease with CLI who were treated with AWBMSCT. We analyzed Rutherford category, pain score, pain-free walking time (PFWT), total walking time (TWT), ankle brachial pressure index (ABPI), and toe brachial pressure index (TBPI), and investigated wound healing and occurrence of unplanned amputations. The mean follow-up duration was 11.9±7.2 months (range, 0.9-23.9 months) and 100%, 72.4%, and 74.1% of patients were available to follow-up 1, 3 and 6 months after AWBMST, respectively. At 6 months, patients demonstrated significant improvements in Rutherford category (P<0.0001), pain score (P<0.0001), PFWT (P<0.0001) and TBPI (P<0.0001). ABPI was increased compared to baseline, but the difference was not significant. A total of 76.5% ischemic wounds achieved complete or improved healing. AWBMSCT is a safe and effective alternative or adjunctive treatment modality to achieve clinical improvement in patients with CLI.

Biomedical Research